A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin

Novo Nordisk

Status: Completed

Conditions: Achondroplasia; Genetic Disorder

Treatments: Drug: somatropin

Study type: Observational

Funder types: Industry

Identifiers

NCT01435629

GH-3907

U1111-1121-7729 (Other Identifier)

JapicCTI-111622 (Other Identifier)

Details and patient eligibility

About

This study is conducted in Japan. The aim of the study is to evaluate the efficacy of somatropin (Norditropin®) on adult height (cm) in patients with achondroplasia / hypochondroplasia enrolled in the GH-1941 study (NCT01516229).

Enrollment: 81 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients who were enrolled in the GH-1941 study (1997 to 2006) and expected to theoretically reach the adult height within the study period

Trial design

81 participants in 1 patient group

Norditropin®

Treatment:

Drug: somatropin